To the Moon Alice, Aethlon Medical stock soars over 400% on North Immunology merger deal

Aethlon Medical (NASDAQ: AEMD) shares rocketed more than 400% in Thursday premarket trading following the announcement of a definitive merger agreement with privately held biotechnology company North Immunology.

Under the all-stock transaction, Aethlon will merge with North Immunology through wholly owned subsidiaries Nighthawk Merger Sub Corp. and Nighthawk Second Merger Sub, LLC. The combined entity will operate as North Immunology, Inc. and trade on the Nasdaq Capital Market under the ticker symbol NRTX.

The merger includes a concurrent private placement expected to provide approximately $180 million in gross proceeds.

The financing was supported by healthcare-focused institutional investors including Bain Capital Life Sciences, Janus Henderson Investors, Deep Track Capital, Longitude Capital, Soleus Capital, Invus, Sirenia Capital Management LP, funds managed by Farallon Capital Management, Adage Capital Partners LP, and TCGX.